ArticleImmunology and cell biology2016
A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs.
Article in Immunology and cell biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- Immunization with a multisubunit vaccine induces immunological memory and cross-protective immunity against heterologousFrontiers in cellular and infection microbiology · 2026Article
- A Cyclic-di-AMP Adjuvanted CPAF Protein Vaccine Is Immunogenic in Swine, but It Fails to Reduce GenitalVaccines · 2025Article
- Antibacterial effects of coniferyl alcohol-derived dehydrogenation polymer on chlamydial infectionFrontiers in chemistry · 2025Article
- Advances inMicroorganisms · 2024Review
- A TriAdj-AdjuvantedVaccines · 2024Article
- Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice.Nature communications · 2024Article
- Review
- Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe.The Lancet regional health. Europe · 2023Review
- Evaluation of three formulations based on Polymorphic membrane protein D in mice infected withFrontiers in immunology · 2023Article
- Management of Pelvic Inflammatory Disease in Clinical Practice.Therapeutics and clinical risk management · 2023Review
- Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections - A review.Saudi journal of biological sciences · 2022Review
- Efficacy of Pgp3 vaccination forFrontiers in immunology · 2022Article
- Host-Pathogen Interactions ofPathogens (Basel, Switzerland) · 2021Article
- Article
- Mucosal Vaccination with UV-InactivatedVaccines · 2020Article
- The pig as a model for immunology research.Cell and tissue research · 2020Review
- Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus.Therapeutic advances in vaccines and immunotherapy · 2020Review
- Parenteral vaccination protects against transcervical infection withNPJ vaccines · 2020Article
- Genital Infiltrations of CD4Frontiers in microbiology · 2019Article
- Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis.Expert review of vaccines · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlamydia is the most widespread sexually transmitted bacterial disease and a prophylactic vaccine is highly needed. Ideally, this vaccine is required to induce a combined response of Th1 cell-mediated immune (CMI) response in concert with neutralizing antibodies. Using a novel Göttingen minipig animal model, we evaluated the immunogenicity and efficacy of a multi-subunit vaccine formulated in the strong Th1-inducing adjuvant CAF01. We evaluated a mixture of two fusion proteins (Hirep1 and CTH93) designed to promote either neutralizing antibodies or cell-mediated immunity, respectively. Hirep1 is a novel immunogen based on the variant domain (VD) 4 region from major outer membrane protein (MOMP) serovar (Sv) D, SvE and SvF, and CTH93 is a fusion molecule of three antigens (CT043, CT414 and MOMP). Pigs were immunized twice intramuscularly with either Hirep1+CTH93/CAF01, UV-inactivated Chlamydia trachomatis SvD bacteria (UV-SvD/CAF01) or CAF01. The Hirep1+CTH93/CAF01 vaccine induced a strong CMI response against the vaccine antigens and high titers of antibodies, particularly against the VD4 region of MOMP. Sera from Hirep1+CTH93/CAF01 immunized pigs neutralized C. trachomatis SvD and SvF infectivity in vitro. Both Hirep1+CTH93/CAF01 and UV-SvD/CAF01 vaccination protected pigs against a vaginal C. trachomatis SvD infection. In conclusion, the Hirep1+CTH93/CAF01 vaccine proved highly immunogenic and equally protective as UV-SvD/CAF01 showing promise for the development of a subunit vaccine against Chlamydia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.